Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 4/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | S100A9 | P06702 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809903 | 0.82 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1STK17BSTK17AS100A9 | |
| SCHEMBL1938007 | 0.80 | STK17A (0.50) | NUDT1ALDH1A1L3MBTL1STK17BSTK17A | |
| SCHEMBL22866258 | 0.79 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1STK17BSTK17AMEN1 | |
| SCHEMBL23142051 | 0.79 | NUDT1 (0.40) | NUDT1ALDH1A1JAK2JAK1MAPK8 | |
| SCHEMBL30718893 | 0.78 | MEN1 (0.46) | NUDT1ALDH1A1L3MBTL1STK17BSTK17A | |
| SCHEMBL4137651 | 0.78 | NUDT1 (0.51) | NUDT1ALDH1A1L3MBTL1STK17BSTK17A | |
| SCHEMBL4134213 | 0.78 | MEN1 (0.46) | NUDT1ALDH1A1L3MBTL1STK17BSTK17A | |
| SCHEMBL3140746 | 0.76 | XDH (0.39) | ALDH1A1L3MBTL1STK17BSTK17AJAK2 | |
| SCHEMBL5436631 | 0.76 | NUDT1 (0.43) | NUDT1ALDH1A1L3MBTL1STK17BSTK17A | |
| SCHEMBL5787248 | 0.76 | MAPK8 (0.43) | NUDT1STK17BSTK17AJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423121-B1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-7112589-B2 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2006-09-26 | — | — | US | disclosed |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | ALTMANN EVA | 2006-04-06 | — | — | US | disclosed |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1423121-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | NUDT1 1614/4885ALDH1A1 2591/4885L3MBTL1 3394/4885 |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | NUDT1 1583/4885ALDH1A1 3065/4885L3MBTL1 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.